Drug intelligence / Profile preview

Collpure

Development stage: Unknown
Lead developer: Parnasa Mediworld
Modality: Small Molecules
Administration: Oral

Overview

**Collpure** is an oral fixed-dose combination tablet marketed by Parnasa Mediworld for osteoarthritis and joint-health management. It contains diacerein, glucosamine sulfate, and methylsulfonylmethane. Diacerein is used to modulate interleukin-1-mediated inflammatory and cartilage-catabolic signaling, while glucosamine sulfate is intended to support cartilage matrix and proteoglycan synthesis; methylsulfonylmethane is a sulfur-containing adjunct used for its proposed anti-inflammatory and analgesic effects. The marketed tablet composition reported for Collpure is diacerein 50 mg, glucosamine 750 mg, and methylsulfonylmethane 250 mg. ([1mg.com](https://www.1mg.com/drugs/collpure-tablet-341320))

Brand names: Collpure
Other names: diacerein + glucosamine sulfate + methylsulfonylmethane

Beyond the preview

Go deeper on Collpure.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Collpure.

Explore the full profile